Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

1.2%

1 terminated/withdrawn out of 86 trials

Success Rate

96.2%

+9.7% vs industry average

Late-Stage Pipeline

19%

16 trials in Phase 3/4

Results Transparency

0 of 25 completed trials have results

Key Signals

23 recruiting

Enrollment Performance

Analytics

N/A

28(38.9%)

Phase 2

23(31.9%)

Phase 3

13(18.1%)

Phase 1

4(5.6%)

Phase 4

3(4.2%)

Early Phase 1

1(1.4%)

72Total

N/A(28)

Phase 2(23)

Phase 3(13)

Phase 1(4)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (86)

Showing 20 of 86 trials

NCT04071704Completed

Assessing Health-related Quality of Life in Sarcoma Patients

Role: collaborator

NCT07546240Not ApplicableRecruiting

Optimal Radiotherapy - Heel Spur Syndrome - Randomized Clinical Trial

Role: lead

NCT06183437Phase 4Recruiting

The STOP-MED CTRCD Trial

Role: collaborator

NCT04943224Phase 2Recruiting

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients

Role: collaborator

NCT04943198Phase 2Recruiting

Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

Role: collaborator

NCT05395741Phase 1Active Not Recruiting

Regorafenib in Patients With Refractory Primary Bone Tumors

Role: collaborator

NCT04943211Phase 3Recruiting

Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging

Role: collaborator

NCT04677998Recruiting

A Personalized Surveillance and Intervention Protocol for Duodenal and Gastric Polyposis in Patients With Familial Adenomatous Polyposis

Role: collaborator

NCT04678011Recruiting

A Personalized Surveillance and Intervention Protocol for Patients With Familial Adenomatous Polyposis That Have Undergone (Procto)Colectomy

Role: collaborator

NCT06128863Phase 2Active Not Recruiting

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

Role: lead

NCT05271162Phase 3Recruiting

Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines

Role: lead

NCT07216157Not ApplicableRecruiting

NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery

Role: lead

NCT05051475Not ApplicableCompleted

Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus

Role: collaborator

NCT04258956Phase 2Completed

A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy

Role: lead

NCT05118178Completed

Atherosclerosis in Chemotherapy-related Cardiotoxicity

Role: lead

NCT06976021Phase 2Not Yet Recruiting

Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy

Role: lead

NCT04398095Not ApplicableCompleted

Radiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas

Role: lead

NCT04875611Phase 2Recruiting

Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment

Role: lead

NCT04861207Phase 2Active Not Recruiting

Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With AML (Acute Myeloid Leukemia) and Myelodysplastic Syndromes

Role: lead

NCT04920968Phase 2Recruiting

Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"

Role: lead